EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Tóm tắt
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to—or adding—another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Từ khóa
Tài liệu tham khảo
Wilske, 1990, Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis, J Rheumatol, 17, 4
McCarty, 1990, Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians, J Rheumatol, 17, 1117
Weinblatt, 1995, Efficacy of methotrexate in rheumatoid arthritis, Br J Rheumatol, 34, 43, 10.1093/rheumatology/XXXIV.suppl_2.43
Visser, 2009, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, 68, 1094, 10.1136/ard.2008.092668
Schumacher, 1993, Primer on the rheumatic diseases, 10
van der Heide, 1996, The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial, Ann Intern Med, 124, 699, 10.7326/0003-4819-124-8-199604150-00001
Huizinga, 2002, Criteria for early rheumatoid arthritis: from Bayes’ law revisited to new thoughts on pathogenesis, Arthritis Rheum, 46, 1155, 10.1002/art.10195
van der Horst-Bruinsma, 1998, Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care, Br J Rheumatol, 37, 1084, 10.1093/rheumatology/37.10.1084
Aletaha, 2005, The need for new classification criteria for rheumatoid arthritis, Arthritis Rheum, 52, 3333, 10.1002/art.21410
Emery, 1995, Early rheumatoid arthritis: time to aim for remission?, Ann Rheum Dis, 54, 944, 10.1136/ard.54.12.944
Smolen, 2014, Proposal for a new nomenclature of disease-modifying antirheumatic drugs, Ann Rheum Dis, 73, 3, 10.1136/annrheumdis-2013-204317
Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461
Smolen, 2016, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, Ann Rheum Dis, 75, 3, 10.1136/annrheumdis-2015-207524
Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573
Singh, 2016, 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 68, 1, 10.1002/acr.22783
van der Heijde, 1993, Development of a disease activity score based on judgment in clinical practice by rheumatologists, J Rheumatol, 20, 579
Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107
Smolen, 2003, A Simplified disease activity index for rheumatoid arthritis for use in clinical practice, Rheumatology (Oxford), 42, 244, 10.1093/rheumatology/keg072
Aletaha, 2005, Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score, Arthritis Res, 7, R796, 10.1186/ar1740
Felson, 2011, American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, Ann Rheum Dis, 70, 404, 10.1136/ard.2011.149765
Kavanaugh, 2013, Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study, Ann Rheum Dis, 72, 64, 10.1136/annrheumdis-2011-201247
van der Heijde, 2012, Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?, Ann Rheum Dis, 71, i89, 10.1136/annrheumdis-2011-200797
Radner, 2014, Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs, Arthritis Res Ther, 16, R56, 10.1186/ar4491
Linde, 2010, Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?, J Rheumatol, 37, 285, 10.3899/jrheum.090898
Provan, 2011, Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study, Ann Rheum Dis, 70, 812, 10.1136/ard.2010.141523
Thiele, 2013, Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis, Ann Rheum Dis, 72, 1194, 10.1136/annrheumdis-2012-201821
Bruynesteyn, 2004, Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months’ follow up, Ann Rheum Dis, 63, 1413, 10.1136/ard.2003.014043
Cohen, 2008, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, Arthritis Rheum, 58, 1299, 10.1002/art.23417
Aletaha, 2016, Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point, Ann Rheum Dis, 75, 1479, 10.1136/annrheumdis-2015-208324
van der Heijde, 2015, 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations, Ann Rheum Dis, 74, 8, 10.1136/annrheumdis-2014-206350
Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 529, 10.1136/annrheumdis-2013-204575
Nam, 2014, Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 73, 516, 10.1136/annrheumdis-2013-204577
Gaujoux-Viala, 2014, Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 510, 10.1136/annrheumdis-2013-204588
Cardiel, 2014, Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis, Reumatol Clin, 10, 227, 10.1016/j.reuma.2013.10.006
Wollenhaupt, 2013, The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint, Z Rheumatol, 72, 6, 10.1007/s00393-012-1093-6
Brenol, 2015, Proper management of rheumatoid arthritis in Latin America. What the guidelines say?, Clin Rheumatol, 34, S51, 10.1007/s10067-015-3016-9
Lau, 2015, APLAR rheumatoid arthritis treatment recommendations, Int J Rheum Dis, 18, 685, 10.1111/1756-185X.12754
European Medicines Agency. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187583.pdf
Gaujoux-Viala, 2014, Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis, Joint Bone Spine, 81, 287, 10.1016/j.jbspin.2014.05.002
Bykerk, 2012, Emerging issues in pharmacological management of rheumatoid arthritis: results of a national needs assessment survey identifying practice variations for the development of Canadian Rheumatology Association clinical practice recommendations, J Rheumatol, 39, 1555, 10.3899/jrheum.110208
Dougados, 2004, EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees, Ann Rheum Dis, 63, 1172, 10.1136/ard.2004.023697
Brouwers, 2010, AGREE II: advancing guideline development, reporting and evaluation in health care, CMAJ, 182, E839, 10.1503/cmaj.090449
Guyatt, 2008, Incorporating considerations of resources use into grading recommendations, BMJ, 336, 1170, 10.1136/bmj.39504.506319.80
Holloway, 2011, The world medicines situation 2011. Rational use of medicines
Schoels, 2010, Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 69, 995, 10.1136/ard.2009.126714
Dörner, 2016, The changing landscape of biosimilars in rheumatology, Ann Rheum Dis, 75, 974, 10.1136/annrheumdis-2016-209166
OCEBM Levels of Evidence Working Group, 2011
Ramiro, 2016, SLR on safety aspects of DMARDs to inform the EULAR RA management task force, Ann Rheum Dis
Nam, 2016, SLR on bDMARDs to inform the EULAR RA management task force, Ann Rheum Dis
Chatzidionysiou, 2016, SLR on csDMARDs to inform the EULAR RA management task force 2016, Ann Rheum Dis
Peters, 2010, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, 69, 325, 10.1136/ard.2009.113696
van der Goes, 2010, Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice, Ann Rheum Dis, 69, 1913, 10.1136/ard.2009.124958
Hoes, 2007, EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis, 66, 1560, 10.1136/ard.2007.072157
van Assen, 2011, EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 70, 414, 10.1136/ard.2010.137216
Strehl, 2016, Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force, Ann Rheum Dis, 75, 952, 10.1136/annrheumdis-2015-208916
Baillet, 2016, Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative, Ann Rheum Dis, 75, 965, 10.1136/annrheumdis-2016-209233
Furst, 2013, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012, Ann Rheum Dis, 72, ii2, 10.1136/annrheumdis-2013-203348
Buch, 2011, Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis, Ann Rheum Dis, 70, 909, 10.1136/ard.2010.144998
Pereira, 2015, Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy, Drug Dev Res, 76, 419, 10.1002/ddr.21285
Smolen, 2013, Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, Ann Rheum Dis, 72, 482, 10.1136/annrheumdis-2012-202469
Strangfeld, 2011, Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?, Ann Rheum Dis, 70, 1914, 10.1136/ard.2011.151043
Zink, 2014, Evaluation of the RABBIT Risk Score for serious infections, Ann Rheum Dis, 73, 1673, 10.1136/annrheumdis-2013-203341
St Clair, 2004, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, Arthritis Rheum, 50, 3432, 10.1002/art.20568
Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7
Breedveld, 2006, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, Arthritis Rheum, 54, 26, 10.1002/art.21519
Smolen, 2014, Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial, Lancet, 383, 321, 10.1016/S0140-6736(13)61751-1
Vastesaeger, 2009, A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis, Rheumatology (Oxford), 48, 1114, 10.1093/rheumatology/kep155
Combe, 2016, 2016 update of the EULAR recommendations for the management of early arthritis, Ann Rheum Dis, 10.1136/annrheumdis-2016-eular.6370
Smolen, 2009, Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor-blockade, Ann Rheum Dis, 68, 823, 10.1136/ard.2008.090019
Smolen, 2006, Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab: results from the ASPIRE trial, Arthritis Rheum, 54, 702, 10.1002/art.21678
van Leeuwen, 1997, Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system, J Rheumatol, 24, 20
Van der Heijde, 1992, Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients, Br J Rheumatol, 31, 519, 10.1093/rheumatology/31.8.519
Scott, 1987, Long-term outcome of treating rheumatoid arthritis: results after 20 years, Lancet, 1, 1108, 10.1016/S0140-6736(87)91672-2
Visser, 2010, A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study, Ann Rheum Dis, 69, 1333, 10.1136/ard.2009.121160
Kiely, 2011, Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN), Rheumatology (Oxford), 50, 926, 10.1093/rheumatology/keq406
Duru, 2013, EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases, Ann Rheum Dis, 72, 1905, 10.1136/annrheumdis-2013-203249
Fransen, 2005, The Disease Activity Score and the EULAR response criteria, Clin Exp Rheumatol, 23, S93
Aletaha, 2005, Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states, Arthritis Rheum, 52, 2625, 10.1002/art.21235
Aletaha, 2006, The definition and measurement of disease modification in inflammatory rheumatic diseases, Rheum Dis Clin North Am, 32, 9, 10.1016/j.rdc.2005.09.005
Stoffer, 2014, Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project, Ann Rheum Dis, 73, 902, 10.1136/annrheumdis-2013-203743
Navarro-Compán, 2015, Quality indicators in rheumatoid arthritis: results from the METEOR database, Rheumatology (Oxford), 54, 1630, 10.1093/rheumatology/kev108
Widdifield, 2011, Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective, Arthritis Care Res (Hoboken), 63, 53, 10.1002/acr.20304
Memel, 2003, General practitioner and specialist care: the perceptions of people with rheumatoid arthritis, Prim Health Care Res Dev, 4, 29, 10.1191/1463423603pc120oa
Robinson, 2010, Time to treatment in rheumatoid arthritis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals, J Clin Rheumatol, 16, 267, 10.1097/RHU.0b013e3181eeb499
Kyburz, 2011, The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study, Rheumatology (Oxford), 50, 1106, 10.1093/rheumatology/keq424
Feldman, 2013, Early consultation with a rheumatologist for RA: does it reduce subsequent use of orthopaedic surgery?, Rheumatology (Oxford), 52, 452, 10.1093/rheumatology/kes231
Nasonov, 2015, Does Russia need a treat-to-target initiative?, Rheumatology (Oxford), 54, 381, 10.1093/rheumatology/keu156
Smolen, 2015, Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges, Nat Rev Rheumatol, 11, 276, 10.1038/nrrheum.2015.8
Cader, 2011, Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort, Ann Rheum Dis, 70, 949, 10.1136/ard.2010.143560
Radner, 2014, Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review, Ann Rheum Dis, 73, 114, 10.1136/annrheumdis-2013-203284
van Aken, 2004, Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis, Ann Rheum Dis, 63, 274, 10.1136/ard.2003.010298
Nell, 2004, Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis, Rheumatology (Oxford), 43, 906, 10.1093/rheumatology/keh199
Moura, 2015, Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study, Arthritis Res Ther, 17, 197, 10.1186/s13075-015-0713-3
Machold, 2010, The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis, Ann Rheum Dis, 69, 495, 10.1136/ard.2009.122473
Verstappen, 2010, Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial, Ann Rheum Dis, 69, 503, 10.1136/ard.2009.119149
Smolen, 2010, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Ann Rheum Dis, 69, 964, 10.1136/ard.2009.126532
Klarenbeek, 2011, The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study, Ann Rheum Dis, 70, 1039, 10.1136/ard.2010.141234
Aletaha, 2007, Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients, Arthritis Rheum, 56, 3226, 10.1002/art.22943
Schipper, 2010, Time to achieve remission determines time to be in remission, Arthritis Res Ther, 12, R97, 10.1186/ar3027
Ranganath, 2015, Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy, Arthritis Care Res (Hoboken), 67, 929, 10.1002/acr.22541
Sakellariou, 2013, In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis, Ann Rheum Dis, 72, 245, 10.1136/annrheumdis-2012-201817
Genovese, 2016, Baricitinib in patients with refractory rheumatoid arthritis, N Engl J Med, 374, 1243, 10.1056/NEJMoa1507247
Gabay, 2013, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541, 10.1016/S0140-6736(13)60250-0
Smolen, 2011, Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants, Arthritis Rheum, 63, 43, 10.1002/art.27740
Fleischmann, 2015, How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?, Ann Rheum Dis, 74, 1132, 10.1136/annrheumdis-2013-204920
Dale, 2016, Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial, Ann Rheum Dis, 75, 1043, 10.1136/annrheumdis-2015-208941
Haavardsholm, 2016, Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial, BMJ, 354, i4205, 10.1136/bmj.i4205
Fleischmann, 2012, Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis, N Engl J Med, 367, 495, 10.1056/NEJMoa1109071
Aletaha, 2008, Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations, Ann Rheum Dis, 67, 1360, 10.1136/ard.2008.091454
Curtis, 2012, Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year, Arthritis Care Res (Hoboken), 64, 658, 10.1002/acr.21600
van der Heijde, 2012, Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial, J Rheumatol, 39, 1326, 10.3899/jrheum.111171
Smolen, 2015, Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with early erosive rheumatoid arthritis (AGREE), Arthritis Res Ther, 17, 157, 10.1186/s13075-015-0671-9
Li, 2016, High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): a multicenter randomized clinical trial, Medicine (Baltimore), 95, e3968, 10.1097/MD.0000000000003968
Choi, 2002, Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, Lancet, 359, 1173, 10.1016/S0140-6736(02)08213-2
Wasko, 2013, Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis, Arthritis Rheum, 65, 334, 10.1002/art.37723
Emery, 2017, Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study, Ann Rheum Dis, 76, 96, 10.1136/annrheumdis-2015-209057
Atsumi, 2016, The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression, Ann Rheum Dis, 75, 75, 10.1136/annrheumdis-2015-207511
Mottonen, 1999, Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group, Lancet, 353, 1568, 10.1016/S0140-6736(98)08513-4
O'Dell, 1996, Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications, N Engl J Med, 334, 1287, 10.1056/NEJM199605163342002
Moreland, 2012, A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial, Arthritis Rheum, 64, 2824, 10.1002/art.34498
O'Dell, 2013, Therapies for active rheumatoid arthritis after methotrexate failure, N Engl J Med, 369, 307, 10.1056/NEJMoa1303006
van Vollenhoven, 2012, Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial, Lancet, 379, 1712, 10.1016/S0140-6736(12)60027-0
de Jong, 2014, Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial, Ann Rheum Dis, 73, 1331, 10.1136/annrheumdis-2013-204788
Verschueren, 2015, Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial, Ann Rheum Dis, 74, 27, 10.1136/annrheumdis-2014-205489
Goekoop-Ruiterman, 2007, Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial, Ann Intern Med, 146, 406, 10.7326/0003-4819-146-6-200703200-00005
Smolen, 2005, Superior efficacy of combination therapy for rheumatoid arthritis. Fact or fiction?, Arthritis Rheum, 52, 2975, 10.1002/art.21293
Landewé, 2014, Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example, Ann Rheum Dis, 73, 1755, 10.1136/annrheumdis-2014-205821
Verschueren, 2017, Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial, Ann Rheum Dis, 10.1136/annrheumdis-2016-209212
Singh, 2012, 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res (Hoboken), 64, 625, 10.1002/acr.21641
Cutolo, 2013, Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen, Rheumatology (Oxford), 52, 1132, 10.1093/rheumatology/kes321
Gaujoux-Viala, 2010, Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 69, 1004, 10.1136/ard.2009.127225
Emery, 2000, A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis, Rheumatology (Oxford), 39, 655, 10.1093/rheumatology/39.6.655
Götestam Skorpen, 2016, The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation, Ann Rheum Dis, 75, 795, 10.1136/annrheumdis-2015-208840
Rau, 2002, Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients, Rheumatology (Oxford), 41, 196, 10.1093/rheumatology/41.2.196
Lehman, 2005, A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study, Arthritis Rheum, 52, 1360, 10.1002/art.21018
Katz, 2011, Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action, Curr Opin Rheumatol, 23, 278, 10.1097/BOR.0b013e32834456bf
Hage, 2014, A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role, Ther Adv Endocrinol Metab, 5, 77, 10.1177/2042018814547204
Sharma, 2016, Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients, J Am Heart Assoc, 5, e002867, 10.1161/JAHA.115.002867
Van der Heijde, 1990, Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up, Lancet, 335, 539, 10.1016/0140-6736(90)90771-V
Strangfeld, 2009, Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide, Ann Rheum Dis, 68, 1856, 10.1136/ard.2008.098467
De Stefano, 2010, Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha, Clin Rheumatol, 29, 517, 10.1007/s10067-009-1349-y
Burmester, 2007, Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial, Ann Rheum Dis, 66, 732, 10.1136/ard.2006.066761
Genovese, 2008, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study, Arthritis Rheum, 58, 2968, 10.1002/art.23940
Goekoop-Ruiterman, 2005, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial, Arthritis Rheum, 52, 3381, 10.1002/art.21405
Nam, 2014, Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study), Ann Rheum Dis, 73, 75, 10.1136/annrheumdis-2013-203440
Buttgereit, 2002, Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology, Ann Rheum Dis, 61, 718, 10.1136/ard.61.8.718
Listing, 2015, Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab, Ann Rheum Dis, 74, 415, 10.1136/annrheumdis-2013-204021
Lahiri, 2015, Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Pract Res Clin Rheumatol, 29, 290, 10.1016/j.berh.2015.05.009
van Sijl, 2014, Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study, PLoS ONE, 9, e87965, 10.1371/journal.pone.0087965
del Rincón, 2014, Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis, Arthritis Rheumatol, 66, 264, 10.1002/art.38210
Choy, 2005, A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs, Ann Rheum Dis, 64, 1288, 10.1136/ard.2004.030908
Taylor, 2015, Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy: results of a phase 3 study [Abstract], Arthritis Rheum, 67, L2
Yoo, 2017, Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis, 76, 355, 10.1136/annrheumdis-2015-208786
Choe, 2017, A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 76, 58, 10.1136/annrheumdis-2015-207764
Emery, 2017, A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 76, 51, 10.1136/annrheumdis-2015-207588
Schoels, 2012, Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis, Ann Rheum Dis, 71, 1303, 10.1136/annrheumdis-2011-200490
Porter, 2016, Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial, Lancet, 388, 239, 10.1016/S0140-6736(16)00380-9
Weinblatt, 2013, Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study, Arthritis Rheum, 65, 28, 10.1002/art.37711
Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med, 358, 676, 10.1056/NEJMoa0706383
Coleman, 2016, Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma, Clin Lymphoma Myeloma Leuk, 16, 175, 10.1016/j.clml.2016.01.004
Emery, 2014, Sustained remission with etanercept tapering in early rheumatoid arthritis, N Engl J Med, 371, 1781, 10.1056/NEJMoa1316133
Detert, 2013, Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study, Ann Rheum Dis, 72, 844, 10.1136/annrheumdis-2012-201612
Bijlsma, 2016, Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial, Lancet, 388, 343, 10.1016/S0140-6736(16)30363-4
Bejarano, 2010, Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis, Rheumatology (Oxford), 49, 1971, 10.1093/rheumatology/keq194
Burmester, 2016, Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial, Ann Rheum Dis, 75, 1081, 10.1136/annrheumdis-2015-207628
Kaneko, 2016, Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study), Ann Rheum Dis, 75, 1917, 10.1136/annrheumdis-2015-208426
Dougados, 2014, Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study, Ann Rheum Dis, 73, 803, 10.1136/annrheumdis-2013-204761
Fleischmann R, Takeuchi T, Schlichting D, et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): phase 3 trial results [abstract]. Arhritis Rheum 2015;67(Suppl 10). http://acrabstracts.org/abstract/baricitinib-methotrexate-or-baricitinib-plus-methotrexate-in-patients-with-early-rheumatoid-arthritis-who-had-received-limited-or-no-treatment-with-disease-modifying-anti-rheumatic-drugs-dmards-p/ (accessed 4 Jan 2016).
Lee, 2012, Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-nave patients with rheumatoid arthritis, Arthritis Rheum, 64, S1049
Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis, 69, 88, 10.1136/ard.2008.105197
Emery, 2015, Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period, Ann Rheum Dis, 74, 19, 10.1136/annrheumdis-2014-206106
Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
Burmester, 2015, Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial, Ann Rheum Dis, 74, 1037, 10.1136/annrheumdis-2013-204769
Smolen, 2016, Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, Lancet, 388, 2763, 10.1016/S0140-6736(16)31651-8
Torrente-Segarra, 2016, VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist, Reumatol Clin, 12, 319, 10.1016/j.reuma.2015.11.019
Manders, 2015, Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial, Arthritis Res Ther, 17, 134, 10.1186/s13075-015-0630-5
Emery, 2013, Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrexate: the PRIZE study, Ann Rheum Dis, 72, 399
Smolen, 2015, Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial, Ann Rheum Dis, 74, 843, 10.1136/annrheumdis-2013-204632
Tanaka, 2013, Discontinuation of biologics in patients with rheumatoid arthritis, Clin Exp Rheumatol, 31, 522
Schett, 2016, Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions, Ann Rheum Dis, 75, 1428, 10.1136/annrheumdis-2016-209201
Fleischmann, 2016, Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab, Arthritis Rheumatol, 68, 2083, 10.1002/art.39714
Dixon, 2012, Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis, Ann Rheum Dis, 71, 1128, 10.1136/annrheumdis-2011-200702
Hazlewood, 2016, Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis, BMJ, 353, i1777, 10.1136/bmj.i1777
Katchamart, 2010, Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis, Cochrane Database Syst Rev, CD008495